

# Nanotechnology in the Development of Smart Drug Delivery Systems

Tiba Salah Mahdi Nassir <sup>1</sup>, Saif Hatem Majeed <sup>2</sup>, Huthaifa Ezzulddin Mohammed Jawaad <sup>3</sup>,  
Mohammed A. Mustafa <sup>4</sup>, Mohammed Hazem Majid <sup>5</sup>

## Abstract

Nanotechnology has emerged as a transformative field in the development of advanced drug delivery systems, offering significant improvements in therapeutic efficacy, targeted delivery, and safety. This review comprehensively explores the integration of nanotechnology in smart drug delivery systems, emphasizing the advancements and challenges in nanocarrier design, including polymeric nanoparticles, carbon nanotubes, hybrid hydrogels, and stimuli-responsive nanomicelles. These innovations have significantly enhanced drug bioavailability, navigated complex biological barriers, and reduced systemic toxicity. The stealth properties of nanocarriers, notably through polymer coatings, have addressed critical challenges such as rapid clearance and opsonization. The review also highlights recent advancements in stimuli-responsive nanomicelles and hybrid nanocarriers, emphasizing their potential for controlled and precise drug release. Furthermore, the importance of nanotechnology in precision medicine is underscored, showcasing its capability to customize treatments and overcome limitations associated with conventional drug delivery systems. Despite considerable progress, ongoing research into biocompatibility, biodegradability, and regulatory frameworks is essential to fully realize clinical applications of nanomedicine. Overall, continuous innovation in nanomaterial design underscores its critical role in addressing complex health conditions, including cancer, Alzheimer's disease, and chronic illnesses, positioning nanotechnology as a cornerstone for future advancements in drug delivery.

**Keywords:** Nanotechnology, Smart Drug Delivery Systems, Nanocarriers, Targeted Drug Delivery, Stimuli-responsive Nanomicelles, Hybrid Nanocarriers, Polymer Coatings, Precision Medicine, Bioavailability, Nanomedicine, Therapeutic Efficacy.

---

<sup>1</sup>College of pharmacy university of Al mustansiriyah

<sup>2</sup>College of Applied Sciences, University of Samarra

<sup>3</sup>Department of Biotechnology, College of Applied Sciences, University of Samarra

<sup>4</sup>Department of Biology, College of Education, University of Samarra

<sup>5</sup>Department of Medical Laboratories, College of Technologies, Al-Turath University

---

## 1. Introduction

The integration of nanotechnology into drug delivery systems has garnered significant attention in recent years, with numerous studies highlighting its potential to revolutionize therapeutic interventions. [1] laid the groundwork by emphasizing the stealth properties of nanocarriers, which enhance therapeutic efficacy through improved drug bioavailability and reduced systemic toxicity. Their review highlights the necessity of polymer coating technologies to prolong the residence time of these carriers in the bloodstream, ultimately enhancing their effectiveness in clinical applications.

Building upon this foundation, [2] expanded the discussion by detailing the broader implications of nanotechnology in drug development. They noted the potential of biodegradable polymeric nanoparticles to deliver drugs, proteins, and DNA to targeted tissues, thereby facilitating more precise treatments. Their work underscores the transformative nature of nanotechnology in healthcare, particularly in the development of innovative medical treatments.

[3] further contributed to this discourse by exploring carbon nanotubes and hybrid hydrogels as promising materials for drug delivery systems. They highlighted the need for innovative drug delivery devices that maximize therapeutic efficacy while ensuring safety. This perspective aligns with the overarching theme of utilizing nanotechnology to enhance the delivery of biological therapeutic agents, which remains a critical area of research.

[4] shifted the focus to targeted drug delivery, identifying the efficiency of nano-technology across various treatment conditions. His review provided insights into both passive and active delivery methods, emphasizing the ability of nanocarriers to navigate biological barriers, such as the blood-brain barrier. This work illustrates the practical applications of nanotechnology in overcoming challenges associated with drug solubility and bioavailability.

[5] explored the use of nanosized materials in the diagnosis and treatment of chronic diseases, emphasizing the importance of size, shape, and surface properties in the efficacy of drug delivery vehicles. Their findings reflect a growing recognition of the role of nanotechnology in enhancing the therapeutic potential of low-soluble drugs, while also addressing safety concerns related to toxicity.

Recent advancements have continued to push the boundaries of nanocarrier technology. [6] discussed the development of hybrid nanocarriers, highlighting the combination of various nanomaterials to improve drug delivery efficacy. They noted the importance of optimizing these systems to achieve targeted drug release, which remains a significant challenge in the field.

[6] built on this narrative by examining nanomicelles as effective carriers for drug delivery. Their review detailed the innovative designs of stimuli-responsive nanomicelles, which can release drugs in response to specific environmental triggers. This approach represents a significant advancement in achieving selective and controlled drug delivery, addressing some of the limitations of traditional methods.

[7] emphasized the critical role of nanotechnologies in overcoming the shortcomings of conventional drug delivery methods. They highlighted how recent developments have led to improved bioavailability and targeted delivery, thereby enhancing the overall efficacy of therapeutic interventions. Their work reflects a broader trend towards precision medicine, where nanotechnology plays a pivotal role in customizing treatments to individual patient needs.

Finally, [8] conducted a systematic review on the impact of nanoparticles in various diseases, including Alzheimer's disease and cancer. Their findings reinforce the versatility of nanoparticles in drug delivery applications, showcasing their ability to minimize adverse effects while boosting treatment effectiveness. This comprehensive analysis underscores the growing relevance of nanotechnology in addressing complex health challenges.

Through these contributions, the literature reveals a dynamic landscape in the development of smart drug delivery systems utilizing nanotechnology, characterized by continuous innovation and a focus on improving therapeutic outcomes.

## 2. Literature review

The article "Stealth Properties to Improve Therapeutic Efficacy of Drug Nanocarriers" by [1] provides a comprehensive overview of the role of nanotechnology in enhancing drug delivery systems, particularly in the treatment of malignancies. The authors emphasize the therapeutic advantages of nanocarriers, which include improved drug bioavailability, extended duration of action, reduced frequency of administration, and lower systemic toxicity. These benefits position nanotechnology as a pivotal element in the advancement of smart drug delivery systems.

One of the critical insights from the article is the challenge of rapid clearance of drug-loaded nanocarriers from the bloodstream due to opsonization by plasma proteins and subsequent recognition by the mononuclear phagocyte system (MPS). The authors discuss how this rapid clearance can limit the therapeutic efficacy of nanocarriers, highlighting the need for innovative strategies to enhance their stealth properties. The review delves into polymer coating technologies that can effectively confer stealth characteristics to nanocarriers, thereby prolonging their residence time in circulation. Specifically, the use of neutral or zwitterionic polymers, noted for their high hydrophilicity and flexibility, is presented as a promising approach to mitigate the recognition and clearance of nanocarriers by macrophages.

The article also addresses the complexities involved in achieving optimal stealth properties. The authors articulate that the organization of the polymer on the nanocarrier surface plays a crucial role in determining its stealth characteristics. This aspect underscores the nuanced relationship between polymer design and biological interactions, as the hydrated polymeric corona, while enhancing stealth, does not render the nanocarrier completely inert to the biological environment. The partial opsonization that occurs despite the polymer coating indicates that while advancements have been made, further research is necessary to fully understand and optimize these interactions.

Moreover, [1] caution that despite the promising developments in stealth nanocarriers, significant work remains to ensure their safety for human applications. The authors call for extensive studies to profile the interactions between nanocarriers and the biological environment, as well as the MPS cell responses triggered upon contact. This critical evaluation of the current state of research highlights the ongoing challenges in the field of nanotechnology and drug delivery systems, emphasizing the need for a thorough understanding of biological interactions to facilitate the successful translation of these technologies into clinical practice.

The article titled "NANOTECHNOLOGY IN NOVEL DRUG DELIVERY SYSTEM" by [2] provides a comprehensive overview of the advancements in nanotechnology and its implications for drug delivery systems. The authors define nanotechnology as the science and engineering involved in the design and application of materials at the nanometer scale, emphasizing its explosive growth and potential benefits in healthcare, particularly in drug development.

One of the key insights presented is the ability of nanotechnology to facilitate targeted drug delivery. The authors discuss the development of biodegradable polymeric nanoparticles that can effectively transport drugs, proteins, and DNA to specific tissues, allowing for controlled release regardless of the administration route. This targeted approach not only enhances the efficacy of treatments but also minimizes side effects by reducing the exposure of non-target tissues to therapeutic agents ([2]).

The article also highlights the potential of nanotechnology in disease prevention, specifically through the use of DNA vaccines. This innovative application could revolutionize how vaccines are administered and improve the immune response. Furthermore, the authors introduce the concept of nanorobots, which could operate within the human body to monitor biochemical levels and store relevant information. This capability suggests a future where real-time health monitoring could lead to timely interventions and personalized medicine ([2]).

Additionally, the authors address the protective role of nanotechnology-based delivery systems in safeguarding drugs from degradation. This is particularly significant as many therapeutic agents are susceptible to environmental factors that can diminish their effectiveness. By utilizing nanotechnology, the stability and bioavailability of drugs can be enhanced, ensuring that patients receive the full therapeutic benefits of their medications ([2]).

The article "Carbon Nanotubes Hybrid Hydrogels in Drug Delivery: A Perspective Review" by [3] presents a comprehensive analysis of the innovative applications of carbon nanotube (CNT) composites in the realm of drug delivery systems. The authors underscore the significance of integrating various materials, including biologics, polymers, silicon, and metals, to enhance the efficacy and safety of therapeutic agents. This review is particularly insightful as it highlights the potential of polymer-carbon nanotube composites in achieving controlled release mechanisms, which is crucial for optimizing drug delivery.

A critical evaluation reveals that the authors effectively articulate the necessity for novel drug delivery systems, especially in light of the evolving landscape of biological therapeutic agents such as nucleic acids and proteins. They argue that the pharmaceutical industry's interest in developing new formulations, driven by patent expirations, further necessitates innovative approaches in drug delivery. This perspective is particularly relevant as it aligns with the growing demand for more efficient and targeted delivery mechanisms in contemporary medicine.

The article also delves into the definition and scope of nanomedicine, emphasizing its role in the monitoring and manipulation of biological systems at the molecular level. The authors provide a compelling argument for the application of nanotechnology in the diagnosis, prevention, and treatment of diseases, noting its potential to revolutionize drug discovery and delivery processes. The discussion surrounding the role of nanomaterials in early detection and diagnosis of conditions such as cancer and infectious diseases is particularly noteworthy, as it highlights the multifaceted benefits of nanotechnology beyond mere drug delivery.

Furthermore, the review addresses the challenges and considerations associated with the use of nanomaterials in drug delivery, including biocompatibility, toxicity, and the need for regulatory frameworks to ensure safety and efficacy. This critical perspective adds depth to the discussion, acknowledging that while the potential of CNTs and hybrid hydrogels is significant, careful consideration of these factors is essential for their successful application in clinical settings.

The article "Mini Review: Nano-Technology based Drug Deliveries" by [4] presents a comprehensive overview of the advancements and applications of nanotechnology in the field of drug delivery systems. The author emphasizes the efficiency of targeted drug delivery methods facilitated by nanotechnology, which have shown promise across various treatment conditions. This review highlights the significance of both passive and active drug delivery mechanisms that utilize nanoparticles as carriers, illustrating their capability to enhance therapeutic efficacy.

One of the key insights from Wang's work is the ability of nanotechnology-based drug carriers to traverse the blood-brain barrier, a significant challenge in treating neurological disorders. This capability is particularly noteworthy as it opens avenues for delivering therapeutics that were previously considered ineffective due to their inability to penetrate this protective barrier. The review underscores the role of nanoparticles in improving the bioavailability of hydrophobic drugs, which often struggle with solubility and absorption in the body. By facilitating the first-pass metabolism, these nano-carriers can ensure that a greater proportion of the drug reaches systemic circulation, thereby enhancing its therapeutic effect.

Wang also discusses the stability of plasma drug levels achieved through nanotechnology-based delivery systems. Unlike conventional methods, which can lead to fluctuating drug concentrations, nanotechnology enables a more controlled release profile, thereby minimizing side effects and improving patient compliance. This stability is particularly beneficial in managing chronic conditions where consistent drug levels are paramount for effective treatment.

Moreover, the article addresses the issue of drug resistance, a common challenge in oncology and infectious diseases. The author points out that nanotechnology can help circumvent resistance mechanisms, providing a strategic advantage in the development of more effective treatment regimens. The low cytotoxicity associated with many nanocarriers further supports their potential for safe application in clinical settings.

The article "Targeted therapy in chronic diseases using nanomaterial-based drug delivery vehicles" by [5] provides a comprehensive overview of the role of nanotechnology in enhancing drug delivery systems, particularly in the context of chronic diseases. The authors effectively highlight the significance of nanomedicine, a burgeoning field that integrates nanoscience with pharmaceutical science to improve therapeutic outcomes.

The review emphasizes the diverse range of nanostructures—organic, inorganic, polymeric, and metallic—that can be employed as drug delivery vehicles. This variety allows for the encapsulation of low-soluble drugs, which traditionally suffer from poor absorption. By utilizing nanomaterials, the authors argue that sustained and controlled drug release can be achieved, thereby improving the bioavailability of these medications. The efficacy of these nanocarriers is critically dependent on several factors, including their size, shape, hydrophobicity, and surface characteristics. The authors note that materials at the nanoscale exhibit a significantly increased surface area, which enhances their interaction with biological environments, thus facilitating more effective drug delivery ([5]).

Moreover, the article discusses the ideal properties of nanomaterials for biomedical applications, emphasizing the importance of high biocompatibility and biodegradability. These characteristics are crucial for minimizing potential toxicity and ensuring patient safety, which remains a significant concern in the clinical application of nanotechnology. The authors acknowledge that while the advantages of nanotechnology in treating chronic diseases are substantial, the associated toxicity risks necessitate further research to establish safety protocols for clinical use.

The article "Recent Advances in Nanocarrier-Assisted Therapeutics Delivery Systems" by [6] presents a comprehensive overview of the advancements in nanocarrier technologies aimed at enhancing drug delivery systems, particularly focusing on dendritic polymers and hybrid nanocarriers. The authors emphasize the importance of modifying dendrimers through strategies such as carboxylation, PEGylation, and acetylation to mitigate their inherent toxicity, which is a significant concern in nanomedicine.

One of the critical insights from the article is the discussion on the limitations of dendrimers, particularly their rapid clearance from the body and short circulation times. These factors pose considerable challenges for their effectiveness as drug delivery systems. To address these issues, the authors highlight the emergence of hybrid nanocarriers, which combine various nanomaterials to improve biocompatibility and drug delivery efficacy. For instance, the exploration of carbon-based hybrid nanogels and their combination with liposomes or polymers represents a promising direction in the field. The authors provide a specific example of a hybrid nanocarrier designed to encapsulate hydrophobic HIV drugs within polymeric cores, which are then integrated into lipid bilayers. This innovative approach not only enhances the targeted delivery of drugs to CD4+ T cells but also significantly reduces the associated toxicity, showcasing the potential of hybrid systems in treating complex diseases.

Moreover, the article underscores the necessity of targeted functionalization in nanocarrier design. Without such modifications, traditional nanocarriers primarily rely on passive accumulation at disease sites due to their small size. The authors advocate for the incorporation of surface ligands that specifically bind to receptors overexpressed in certain cancer cells, thereby improving the precision of drug delivery. This targeted approach is crucial for maximizing therapeutic outcomes and minimizing side effects.

The discussion on stimuli-responsive nanocarriers further enriches the article, indicating the ongoing research aimed at developing systems that can release drugs in response to specific biological triggers. This adaptability could lead to more effective treatment regimens by allowing for controlled drug release rates, which is essential for managing diseases with dynamic therapeutic needs.

The article "Recent Advances in Nanomicelles Delivery Systems" by [6] provides a comprehensive overview of the advancements in nanomicelle technology as a means of enhancing drug delivery systems. The authors effectively articulate the challenges associated with the selective delivery of therapeutic drugs, emphasizing that these challenges represent a significant barrier to the development of new pharmacological interventions.

Nanomicelles are highlighted as promising nanocarriers due to their advantageous properties, including their diminutive size, biocompatibility, and ability to encapsulate lipophilic drugs effectively. These characteristics position nanomicelles as ideal candidates for improving the pharmacokinetics of poorly soluble drugs, which often hinder therapeutic efficacy. The article discusses the innovative designs of stimuli-responsive nanomicelles that facilitate the targeted release of drugs in response to specific endogenous or exogenous stimuli. This aspect is particularly noteworthy as it underscores the potential for achieving precise drug delivery, thereby minimizing off-target effects and enhancing therapeutic outcomes.

The authors also provide a critical evaluation of the current limitations in the field, such as the challenges of controlling drug release and the extensive biodistribution of therapeutic agents. They argue that despite the progress made in the design of nanocarriers, the complexity of biological systems often results in unpredictable pharmacokinetic profiles, which can complicate the clinical translation of these technologies. This acknowledgment of existing barriers is crucial for guiding future research directions and underscores the need for continued innovation in nanotechnology-based drug delivery systems.

Furthermore, the review emphasizes the importance of ongoing research into targeted nanomedicines that aim to mitigate toxicity while improving the efficacy of drug delivery. The authors suggest that as the field evolves, a deeper understanding of the interactions between nanocarriers and biological systems will be essential for overcoming the current challenges faced in drug delivery.

The article "Precise Design Strategies of Nanotechnologies for Controlled Drug Delivery" by [7] presents a comprehensive overview of the advancements in nanotechnology aimed at enhancing drug delivery systems. The authors argue that mobilizing cellular and microenvironment responses through innovative drug delivery mechanisms is essential in combating diseases effectively. This perspective highlights the critical need for drug delivery systems that not only improve bioavailability but also enhance therapeutic efficacy while minimizing adverse effects.

One of the primary contributions of this article is its critical examination of conventional drug delivery methods, which are characterized by several limitations. The authors detail how traditional approaches often suffer from reduced effectiveness in targeting specific cells and organs, as well as the risk of inactivation or degradation during transit across biological barriers. They emphasize that these methods frequently result in a burst release of drugs, leading to increased cytotoxicity and side effects. This analysis underscores the necessity for more sophisticated delivery systems that can address these shortcomings.

In contrast, the authors present nanotechnology-based drug delivery platforms as a solution to these challenges. They explain that nanoparticles enhance the stability and solubility of drugs, facilitating their transport across cell membranes and improving their targeting capabilities. The review articulates how nanotechnologies can be engineered to ensure maximum potency and durability of therapeutic agents while simultaneously reducing side effects. This assertion is supported by a discussion of various design strategies that allow for cell-specific targeting and prolonged circulation times, which are critical for the successful delivery of drugs.

Furthermore, Huang and Ding (2022) delve into the implications of precision medicine in the context of nanotechnology. They argue that tailored treatment plans, which consider genetic and epigenetic characteristics of patients, can significantly benefit from advancements in nanotechnology-based drug delivery systems. This perspective highlights the potential for these technologies to address patient heterogeneity, thereby improving drug specificity and optimizing dosing regimens.

The article also touches on the biological barriers that drug delivery systems must overcome and highlights recent progress in both in vivo and transdermal applications. This discussion is particularly relevant as it situates the advancements in nanotechnology within the broader landscape of drug delivery challenges, providing a clear context for the importance of these innovations.

The article titled "Impact of nanoparticles on amyloid  $\beta$ -induced Alzheimer's disease, tuberculosis, leprosy and cancer: a systematic review" by [8] provides a comprehensive examination of the role of nanoparticles in various medical applications, particularly focusing on their potential in drug delivery systems. The authors present a systematic review that underscores the transformative impact of reducing bulk materials to the nanoscale, which alters their physicochemical properties and enhances their applicability in the biomedical field.

One of the key insights from the article is the unique characteristics of nanoparticles, particularly their large surface area-to-volume ratio, which significantly increases their reactivity. This property is crucial in the context of drug delivery, as it facilitates the transport and interaction of nanoparticles with therapeutic agents. The authors effectively highlight how these nanoparticles can minimize the adverse effects commonly associated with chemotherapy, thereby improving treatment outcomes. This assertion is particularly relevant in the current landscape of cancer treatment, where the precision and specificity of drug delivery are paramount.

Moreover, the article discusses the flexibility offered by nanomaterials in tailoring drug release characteristics, biodistribution, cellular uptake, targeting, and immunogenicity. This adaptability is essential for optimizing therapeutic strategies and enhancing the efficacy of treatments. The authors emphasize that many physiological processes occur at the nanoscale, making nanoparticles ideally suited for drug delivery applications. This assertion is supported by empirical evidence and aligns with current trends in nanotechnology research.

Chakraborty et al. also address the potential for nanoparticles to form stable interactions with ligands, which enhances their capacity as carriers for therapeutic molecules. This capability is particularly significant for target-specific and controlled delivery systems, as it allows for the precise administration of drugs to affected tissues or cells, thereby maximizing therapeutic effects while minimizing systemic exposure.

However, while the article provides a thorough overview of the benefits of nanoparticles in drug delivery, it would benefit from a more detailed discussion of the challenges and limitations associated with their use. For instance, the potential toxicity of certain nanoparticles, their long-term effects in biological systems, and regulatory hurdles in clinical applications warrant further exploration. Addressing these concerns could provide a more balanced perspective on the implications of nanotechnology in healthcare.

### **3. Conclusion**

The integration of nanotechnology into drug delivery systems has emerged as a transformative approach in therapeutic interventions, significantly enhancing drug bioavailability, reducing systemic toxicity, and improving overall treatment efficacy. The literature indicates that various nanocarriers, including polymer-coated nanoparticles, carbon nanotubes, and hybrid nanocarriers, are pivotal in the development of smart drug delivery systems.

The foundational work by [1] emphasizes the stealth properties of nanocarriers, which are crucial for prolonging the circulation time of drugs in the bloodstream, thereby enhancing therapeutic effectiveness. The use of polymer coatings is particularly noteworthy, as these coatings can mitigate rapid clearance by the mononuclear phagocyte system, allowing for a more sustained therapeutic effect. This is complemented by findings from [2], which highlight the potential of biodegradable polymeric nanoparticles in delivering a variety of therapeutic agents to targeted tissues, further supporting the precision of treatments.

The exploration of innovative materials, such as carbon nanotubes and hybrid hydrogels, as discussed by [3], underscores the importance of developing novel drug delivery systems that maximize efficacy while ensuring safety. This aligns with the insights provided by [4], who elaborates on the capability of nanocarriers to navigate biological barriers, including the blood-brain barrier, thereby enhancing the delivery of therapeutics that are otherwise limited by solubility issues.

Further advancements in targeted drug delivery are illustrated by [5], who emphasizes the critical role of nanosized materials in improving the therapeutic potential of low-soluble drugs, while also addressing safety concerns. Recent innovations in hybrid nanocarriers, as discussed by , highlight the importance of combining various nanomaterials to enhance drug delivery efficacy and achieve targeted release, which remains a significant challenge in the field.

The development of stimuli-responsive nanomicelles, as explored by [6], represents a significant leap towards achieving controlled drug delivery, addressing limitations of traditional methods. Additionally, the critical evaluation by [7] reinforces the necessity of innovative drug delivery mechanisms that not only improve bioavailability but also tailor treatments to individual patient needs through precision medicine.

Finally, the systematic review conducted by [8] encapsulates the versatility of nanoparticles in drug delivery applications, showcasing their ability to minimize adverse effects while enhancing treatment effectiveness across various diseases. This comprehensive analysis underscores the growing relevance of nanotechnology in addressing complex health challenges and improving therapeutic outcomes.

In conclusion, the literature reveals a dynamic and rapidly evolving landscape in the development of smart drug delivery systems utilizing nanotechnology. The continuous innovation in nanocarrier design and application demonstrates the potential to significantly enhance therapeutic efficacy, address safety concerns, and ultimately improve patient outcomes in clinical practice.

## References:

1. S. Salmaso and P. Caliceti, "Stealth Properties to Improve Therapeutic Efficacy of Drug Nanocarriers," 2013. ncbi.nlm.nih.gov
2. A. Kapil, G. Aggarwal, and S. L. Harikumar, "NANOTECHNOLOGY IN NOVEL DRUG DELIVERY SYSTEM," 2014. [PDF]
3. G. Cirillo, S. Hampel, U. Gianfranco Spizzirri, O. Ilaria Parisi et al., "Carbon Nanotubes Hybrid Hydrogels in Drug Delivery: A Perspective Review," 2014. ncbi.nlm.nih.gov
4. K. Wang, "Mini Review: Nano-Technology based Drug Deliveries," 2018. [PDF]
5. A. Pratap Singh, A. Biswas, A. Shukla, and P. Maiti, "Targeted therapy in chronic diseases using nanomaterial-based drug delivery vehicles," 2019. ncbi.nlm.nih.gov
6. S. M. Tawfik, S. Azizov, M. R. Elmasry, M. Sharipov et al., "Recent Advances in Nanomicelles Delivery Systems," 2020. ncbi.nlm.nih.gov
7. S. Huang and X. Ding, "Precise Design Strategies of Nanotechnologies for Controlled Drug Delivery," 2022. ncbi.nlm.nih.gov
8. A. Chakraborty, S. S. Mohapatra, S. Barik, I. Roy et al., "Impact of nanoparticles on amyloid  $\beta$ -induced Alzheimer's disease, tuberculosis, leprosy and cancer: a systematic review," 2023. ncbi.nlm.nih.gov